Susquehanna International Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Susquehanna International Group’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.2M	Buy	601,600 +112,500	+23%	+$1.86M	﹤0.01%	2938
2025 Q4	$6.45M	Sell	489,100 -62,400	-11%	-$736K	﹤0.01%	3640
2025 Q3	$3.95M	Buy	551,500 +420,500	+321%	+$21.9M	﹤0.01%	4492
2025 Q2	$6.18M	Buy	131,000 +64,200	+96%	+$2.62M	﹤0.01%	3602
2025 Q1	$2.61M	Buy	66,800 +18,200	+37%	+$784K	﹤0.01%	4955
2024 Q4	$2.63M	Buy	48,600 +30,100	+163%	+$1.54M	﹤0.01%	4712
2024 Q3	$933K	Sell	18,500 -32,200	-64%	-$1.51M	﹤0.01%	6947
2024 Q2	$2.23M	Buy	50,700 +8,300	+20%	+$352K	﹤0.01%	4889
2024 Q1	$2.13M	Buy	42,400 +10,400	+33%	+$564K	﹤0.01%	5190
2023 Q4	$1.93M	Sell	32,000 -1,000	-3%	-$51.5K	﹤0.01%	5433
2023 Q3	$1.88M	Buy	+33,000	New	+$1.82M	﹤0.01%	5260

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group's MLTX Position: Q1 2026 in Review

Susquehanna International Group reduced its MoonLake Immunotherapeutics (MLTX) stake by 38% in Q1 2026, selling an estimated $3.44M and leaving 341,424 shares worth $6.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3838.

Susquehanna International Group first reported a position in MLTX in Q3 2023 and has held it in 7 quarters since. The position peaked at $12.9M in Q4 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Susquehanna International Group held 341,424 shares of MoonLake Immunotherapeutics worth $6.36M as of Q1 2026.
Susquehanna International Group sold 207,812 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $3.44M.
MoonLake Immunotherapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3838 holding.
Susquehanna International Group first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 7 quarters since.
Susquehanna International Group's MoonLake Immunotherapeutics position peaked at $12.9M in Q4 2023.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.